Houlihan Lokey, Inc.

▲ Bull Case

• ◆Q4 FY2026 miss is deal timing, not cycle: Q3 FY2026 was a record $717M; pipelines were full; advisory Q4 misses follow Q3 records in ~75% of historical cases. If Q1 FY2027 (August 2026) reports $650M+ revenue, the timing interpretation is confirmed and the stock re-rates immediately to $240–$260, delivering 12–20% return in 3–4 months.
• ◆Financial Restructuring cycle building: The 2020–22 LBO vintage maturity wall, elevated credit spreads, and a 12–24 month lag from stress to fee realization point to a FR revenue surge to $700–$850M in FY2027–28 (vs. $529M in FY2026). In 4 of 4 advisory downturns since 2008, FR surged when CF fell — this structural floor is unique among public advisory peers.
• ◆Secular compounder with irreplicable market position: #1 in M&A deal count, #1 in restructuring, #1 in fairness opinions since 2000. PE sponsor relationships are sticky (sponsors do 5–10 deals/yr through HLI); boards seek the recognized #1 for legal cover. Adj. EPS expected to grow from $7.56 (FY2026) to ~$11.75 (FY2029), with ROE expanding toward 27%, supporting a 21–28x multiple and a stock price of $250–$295 over three years.

▼ Bear Case

• ◆Q4 miss signals cycle turn, not timing: UBS already trimmed to Neutral. If macroheadwinds (tariffs, elevated rates, slowing PE deployment) are suppressing deal demand rather than shifting it, Q1 FY2027 will also disappoint (<$600M). Consensus EPS cuts would begin, and the multiple could compress toward the 20–22x EVR/LAZ range, implying a stock price of $180–$200.
• ◆Restructuring never surges (soft landing scenario): If the Fed achieves a soft landing, defaults remain low, and the maturity wall is refinanced rather than restructured, FR revenues stay flat near $530M rather than rising to $700–$850M. With CF also constrained by rate/macro headwinds, both segments disappoint simultaneously — the all-weather model fails to produce the expected earnings floor.
• ◆Governance and talent risks cap the multiple: The Voting Trust structure creates a persistent governance discount relative to fully independent peers. A bulk departure of 10+ senior MDs in any vertical would impair client relationships and moat immediately. These risks, combined with SBC that roughly offsets buybacks and a modest 1.2% dividend yield, limit total yield to ~2.7–4%/yr and make it difficult to justify paying above 28x adj. EPS.

“The central debate is whether the Q4 FY2026 earnings miss is a deal timing issue or a signal of a broader M&A cycle turn. Bulls point to the record Q3 FY2026 ($717M), a historically full pipeline, and the pattern that advisory Q4 misses follow Q3 records ~75% of the time — implying deals slipped into Q1 FY2027. Bears, including UBS (trimmed to Neutral), cite macro headwinds from tariffs, persistently elevated rates, and slowing PE deployment as evidence of genuine demand weakness. The secondary debate concerns restructuring: bulls see the 2020–22 LBO vintage maturity wall and elevated credit spreads as precursors to a major FR revenue surge in FY2027–28, while bears argue a Fed soft landing keeps defaults low and FR flat. Both debates resolve at the Q1 FY2027 earnings report (August 2026), making that the single highest-priority data point for the investment thesis.”

• ◆Q1 FY2027 earnings (August 2026): Revenue $650M+ confirms Q4 miss as deal timing slippage; immediate stock re-rating to $240–$260 (+12–20%)
• ◆FR revenue $580M+ in Q1/Q2 FY2027: Restructuring cycle acceleration acknowledged by management; Variant 2 confirmed; multiple expands
• ◆Fed rate cuts accelerating PE dry powder deployment: M&A activity rebounds; CF re-rates toward cycle-peak multiples
• ◆Voting Trust governance disclosure or partial unwinding timeline: Governance premium narrows; institutional buyers expand the eligible universe
• ◆FY2028 restructuring cycle peak: FR revenues reaching $650–$850M as LBO vintage maturities convert to mandates; adj. EPS approaching $10.50

• ◆Q1 FY2027 revenue below $600M: Confirms cycle signal interpretation; consensus EPS cuts begin; multiple contracts to 20x; stock falls to $180–$200
• ◆FR revenue flat or declining in FY2027 while CF also declines: All-weather model fails; both segments deteriorate simultaneously; thesis breaks
• ◆10+ senior MD departures in a 12-month period: Advisory moat is human capital; bulk departures mean client relationships walk; moat materially impaired
• ◆Adj. operating margin below 17% for 2 consecutive quarters: Comp structure breaking down; unusual cost event (severance/retention); earnings quality concern
• ◆Voting Trust controversy or forced dissolution without succession plan: Governance uncertainty spikes; institutional selling pressure; premium multiple at risk
• ◆Multiple compression to EVR/LAZ range (18–22x): If governance discount widens or macro deteriorates, re-rating alone would push stock to $162–$198 on FY2027E EPS